Face Pharma will increase your profits. The Spanish laboratory closed 2022 with a profit of 89.5 million eurosThis translates into an 8.6% increase compared to 2021 results, the group reported in a statement sent to the National Securities Market Commission (Cnmv) this Tuesday.
The pharmaceutical company In 2022, payment of 462 million euros, an increase of 7.7%, gross operating profit (EBITDA) of 6%, up to 121 million euros, despite the increase in costs.
The company met its forecast for the year due to the pressure of the international marketIt grew by 17%, up to 160 million euros, in contrast to the 1% decrease in the national market. These changes have widened the weight gap in revenue to overseas markets, which already account for 54 percent of the pharmaceutical group.
Face Pharma grew especially in Latin America, where its business volume increased by 21 percent last year.
Regionally, Face Pharma grew particularly in Latin America, where its business volume rose by 21% last year, to report revenues of 79.2 million euros compared to 65.3 million euros the previous year.
In Europe, FacePharma’s revenue returned by 8%, up to 40.3 million eurosPortugal is its biggest market in terms of sales, contributing 31.3 million euros to the group in 2022, up from 28.4 million euros a year ago.
Company highlights include Bilastin ophthalmic approval in EuropeWhose launch in the middle of 2022, parent bilastine for acute allergic processes and calcifediol soft gelatin capsules granted patent in Brazil.
The pharmaceutical company employs a total of 1,678 people.
In the year Founded in 1933, Fes Pharma is a Spanish pharmaceutical company with extensive international experience in researching, manufacturing and marketing pharmaceutical products and raw materials, exporting them to many countries.
The company, which has 1,678 people and a headquarters, manufacturing and research, development and innovation (R + D + i) center in Vizcaya, has offices in Madrid and Barcelona and in Portugal (Laboratorios Vitoria), Italy (poured, 51). %), Mexico, Guatemala, Colombia, Chile, Peru, Ecuador and Nigeria.
Among the recent works of the company, the purchase of Novosisys stands outA pharmaceutical company located in the United Arab Emirates will allow it to strengthen its presence in the region.
NovoSci’s portfolio includes products such as eye care, skin care, nasal care, pain relief and nutritional supplements, among others. Face Pharma’s main treatments are Bilaxten, a drug to relieve the symptoms of allergic rhinitis and urticaria; Claversal, intestinal anti-inflammatory, Hidroferol, Venosmil, Hemorrane and Dynamogen.